Tovorafenib 25 mg/ml Suppliers & Bulk Manufacturers

Available Forms: Oral suspension

Available Strengths: 25 mg/ml

Reference Brands: Ojemda (USA)

Category: Oncology Cancer Care

Tovorafenib is a Oncology Cancer Care product available as Oral suspension in strengths 25 mg/ml. It corresponds to the reference brand Ojemda (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Tovorafenib is an oral targeted therapy used for the treatment of glioma, particularly in patients with tumors driven by abnormal RAF signaling. It is a type II RAF kinase inhibitor designed to selectively block aberrant RAF activity, which plays a critical role in tumor cell growth and survival. By inhibiting this pathway, tovorafenib helps slow disease progression and supports tumor control in affected patients.

Marketed under the brand name Ojemda, tovorafenib is used in oncology care where precise molecular targeting is essential. It has demonstrated clinical benefit in patients with glioma and is administered orally, offering a convenient treatment option compared with invasive therapies. As a targeted agent, tovorafenib requires careful patient selection and monitoring to optimize therapeutic outcomes.

Common adverse reactions associated with tovorafenib therapy include rash, fatigue, hair color changes, headache, nausea, vomiting, dry skin, constipation, fever, and upper respiratory tract infections. Laboratory abnormalities may include changes in phosphate, hemoglobin, liver enzymes, creatinine phosphokinase, electrolytes, and blood cell counts. Due to these effects, routine clinical and laboratory monitoring is recommended during treatment. Tovorafenib represents an important advancement in precision oncology for glioma management.